BUNDESANSTALT FUER ARBEITSSCHUTZ UND ARBEITSMEDIZIN

Their core work

BAuA is Germany's Federal Institute for Occupational Safety and Health, the government's central research and advisory body on workplace safety, occupational medicine, and chemical risk assessment. They develop regulatory-grade test methods and risk governance frameworks, particularly for emerging materials like nanomaterials and microplastics. Their applied research feeds directly into EU and OECD regulatory processes — from REACH compliance to harmonised test guidelines — making them a bridge between laboratory science and policy implementation. They also investigate human-robot interaction safety and worker ergonomics in modern manufacturing environments.

What they specialise in

How they've shifted over time

BAuA's early H2020 work (2016–2019) centred on fundamental toxicology — systems toxicology, adverse outcome pathways, computational modelling, and chemical risk assessment through EU-ToxRisk. From 2019 onward, their focus broadened in two directions: they moved upstream into risk governance and regulatory harmonisation (Gov4Nano, NanoHarmony, HARMLESS), and simultaneously expanded into physical workplace safety — worker ergonomics, human-robot collaboration, and wearable monitoring in manufacturing (SOPHIA, BIONIC). This represents a clear evolution from lab-based toxicology toward applied occupational safety and regulatory policy.

BAuA is moving from generating risk data in the lab to shaping how that data gets used in regulation and workplace practice — expect future projects at the intersection of occupational safety, emerging materials governance, and Industry 4.0 worker protection.

How they like to work

BAuA operates predominantly as a specialist partner (6 of 7 projects), contributing domain expertise in risk assessment and regulatory science to large consortia. They coordinated one project (NanoHarmony), which was also their highest-funded, suggesting they take the lead when the topic aligns tightly with their regulatory mandate. With 123 unique partners across 24 countries, they are well-networked but not a serial coordinator — they bring credibility and regulatory know-how rather than project management infrastructure.

BAuA has collaborated with 123 unique partners across 24 countries, indicating a broad European network. As a German federal institute, they connect naturally to regulatory bodies, universities, and industry across the EU, with no apparent geographic bias beyond the typical Western European research core.

What sets them apart

BAuA's value lies in being a federal regulatory authority that actively participates in research — they don't just study risks, they write the rules. For consortium builders, this means having a partner whose findings carry direct weight with OECD, REACH, and national regulators. Few organizations combine deep toxicology expertise with occupational safety mandates and the authority to translate research into binding guidelines.

Highlights from their portfolio

• NanoHarmony
  BAuA's only coordinated project and largest funding (EUR 520K) — directly aimed at creating OECD test guidelines for nanomaterials, demonstrating their regulatory authority.
• EU-ToxRisk
  A flagship EU programme on mechanism-based toxicity testing involving major European partners — BAuA contributed despite modest funding (EUR 53K), indicating prestige-driven participation.
• SOPHIA
  Their largest participation funding (EUR 360K) and a departure from chemical safety into human-robot collaboration and Industry 4.0 worker protection — signals strategic diversification.